Androgen receptor expression and breast cancer mortality in a population-based prospective cohortReportar como inadecuado

Androgen receptor expression and breast cancer mortality in a population-based prospective cohort - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Breast Cancer Research and Treatment

pp 1–13

First Online: 22 June 2017Received: 30 March 2017Accepted: 13 June 2017DOI: 10.1007-s10549-017-4343-0

Cite this article as: Elebro, K., Bendahl, PO., Jernström, H. et al. Breast Cancer Res Treat 2017. doi:10.1007-s10549-017-4343-0


PurposeThe increase in clinical trials with androgen receptor AR-targeting drugs emphasizes the need of clarifying the role of AR expression in different breast cancer subtypes. AR confers good prognosis in estrogen receptor positive ER+ breast cancer, but its role in ER-negative ER− breast cancer is unclear. The aim of this study was to elaborate on previous findings of a differential prognostic role for AR depending on ER status, using breast cancer mortality BCM as endpoint, in a population-based cohort from the Malmö Diet and Cancer Study.

MethodsImmunohistochemical AR expression was assessed in 910 women with invasive breast cancer diagnosed 1991–2010, supplemented with clinicopathological information, vital status, and cause of death, with the last follow-up in December 2014 median 10 years. Survival analyses according to AR status and AR-ER combinations were performed.

ResultsAR expression was available for 671 tumors. AR+ n = 573, 85% was associated with favorable established tumor markers and lower BCM in univariable analysis, especially during the first 5 years following diagnosis HR 0.4; 95% confidence intervals CI 0.2–0.7. Multivariable analysis for short-term follow-up indicated higher BCM among patients with AR+ER− tumors HR 3.5; 95% CI 1.4–9.1 than other AR and ER combinations.

ConclusionsAR expression added prognostic information to ER expression with respect to short-term prognosis. The worst prognosis was seen for patients with AR+-ER− tumors in short-term follow-up, supporting the pre-specified hypothesis. However, larger cohorts are needed for further characterization of the role of AR expression in ER− breast cancer.

KeywordsBreast cancer Androgen receptor Estrogen receptor Prognostic marker Breast cancer mortality AbbreviationsALNIAxillary lymph node involvement

ARAndrogen receptor

BCMBreast cancer mortality

CBCMCumulative breast cancer mortality

CIConfidence interval

CMCumulative all-cause mortality

DFSDisease-free survival

EREstrogen receptor alpha

HER2Human epidermal growth factor receptor -2

HRHazard ratio


IQRInterquartile range

ISHIn situ hybridization

Ki67Proliferation associated antigen

LARLuminal AR

MDCSMalmö Diet and Cancer Study

PRProgesterone receptor

TMATissue microarray

TNBCTriple-negative breast cancer

Autor: Karin Elebro - Pär-Ola Bendahl - Helena Jernström - Signe Borgquist


Documentos relacionados